Clinical trial
A Prospective, Open Study on the Safety and Effectiveness of CellBooster® Glow (Stabilized Hyaluronic Acid-based Complex) on Healthy Participants
NCT07929870 is registered in ClinicalTrials.gov with Suisselle as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open Study on the Safety and Effectiveness of CellBooster® Glow (Stabilized Hyaluronic Acid-based Complex) on Healthy Participants
- Lead sponsor
- Suisselle
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- February 1, 2027
- Completion date
- August 31, 2027
- Enrollment
- 60 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
dark eye circles (periorbital hyperpigmentation), skin hydration in healthy volunteers, skin laxity, skin pigmentation, wrinkle appearance
Arms
As registered; 1 arm.
-
CellBooster® Glow facial injection
An initial injection session will be performed at visit 2 (D0). A second injection session will be performed at visit 3 (D14). And a third injection session will be performed at visit 4 (D28).
CellBooster® Glow (CBG) Class III medical device
Composition:
* non-crosslinked Sodium Hyaluronate 18 mg
* amino acids (Cysteine, Glutathione, Glycine, Lysine, Proline, Valine)
* vitamins (Sodium Ascorbyl Phosphate, Biotin)
* phosphate buffer pH 6.8-7.6 q.s
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change from baseline recorded at visit 1 (Day -7 to Day 0) of epidermis hydration measured with Corneometer® at Day 42.
At each visit, five measurements will be taken on the right cheekbone, a few centimeters below the outer corner of the eye. The recorded value will be the average of the five measurements An improvement of epidermis hydration is defined as an increase higher than 2AU.
Lead sponsor's other trials
Suisselle, most recent start first.
Similar trials
Same condition (Injection Site Reaction) and phase, most recent start first.
+1 more trial See the condition page